All News
-
A Novel RBD-Protein/Peptide Vaccine Elicits Broadly Neutralizing Antibodies and Protects Mice and Macaques against SARS-CoV-2
A Novel RBD-Protein/Peptide Vaccine Elicits Broadly Neutralizing Antibodies and Protects Mice and Macaques against SARS-CoV-2A Novel RBD-Protein/Peptide Vaccine Elicits Broadly Neutralizing Antibodies and Protects Mice and Macaques against SARS-CoV-2more -
UB-612 Multitope Vaccine targeting both Spike and Non-Spike Proteins of SARS-CoV-2 Provides Broad and Durable Immune Responses
UB-612 Multitope Vaccine targeting both Spike and Non-Spike Proteins of SARS-CoV-2 Provides Broad and Durable Immune ResponsesUB-612 Multitope Vaccine targeting both Spike and Non-Spike Proteins of SARS-CoV-2 Provides Broad and Durable Immune Responsesmore -
IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE-downregulation and relieves urticaria symptoms
IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE-downregulation and relieves urticaria symptomsIgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE-downregulation and relieves urticaria symptomsmore -
High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster UB-612
High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster UB-612High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster UB-612more -
UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of Concern
UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of ConcernUB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of Concernmore -
A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants
A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variantsA multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variantsmore -
Potent Anti-Delta Effect By a Booster Third-Dose of UB-612, a Precision-Designed SARS-CoV-2 Multitope Protein-Peptide Vaccine
Potent Anti-Delta Effect By a Booster Third-Dose of UB-612, a Precision-Designed SARS-CoV-2 Multitope Protein-Peptide VaccinePotent Anti-Delta Effect By a Booster Third-Dose of UB-612, a Precision-Designed SARS-CoV-2 Multitope Protein-Peptide Vaccinemore -
A Novel SARS-CoV-2 RBD-Protein/T Cell Peptide Multitope Vaccine Elicited Neutralizing Antibodies against Multiple Variants of Concerns: T cell Immunity and Protection Against Respiratory Infection in Mice and Non-Human Primates
A Novel SARS-CoV-2 RBD-Protein/T Cell Peptide Multitope Vaccine Elicited Neutralizing Antibodies against Multiple Variants of Concerns: T cell Immunity and Protection Against Respiratory Infection in Mice and Non-Human PrimatesA Novel SARS-CoV-2 RBD-Protein/T Cell Peptide Multitope Vaccine Elicited Neutralizing Antibodies against Multiple Variants of Concerns: T cell Immunity and Protection Against Respiratory Infection in Mice and Non-Human Primatesmore -
Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption
Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment InterruptionEffect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruptionmore -
TIME magazine report - How an Experimental Injection Could Revolutionize HIV Treatment
How an Experimental Injection Could Revolutionize HIV TreatmentTIME magazine report - How an Experimental Injection Could Revolutionize HIV Treatmentmore -
J.P. Morgan Roundtable: Financing Challenges, And Opportunities, For Complex Therapies
Part 1: Scrip spoke with companies working on cell and gene therapies and novel neuroscience platforms – areas difficult to finance in the past, but seeing increasing investor interest – about funding challenges and opportunities in 2019.J.P. Morgan Roundtable: Financing Challenges, And Opportunities, For Complex Therapiesmore -
Alzheimer’s vaccine shows promise in early stages
For two decades, biotech companies trying to tackle Alzheimer’s disease have had little success. While vaccines have often shown promise for certain patients, they’ve come with devastating side effects for others—brain swelling, for example—because researchers haven’t been able to reliably keep patients’ immune systems from kicking into overdriveAlzheimer’s vaccine shows promise in early stagesmore
